The Inscripta® Blog
May 17, 2022
Aldevron Licenses the Manufacturing of MAD7™ Nuclease from Inscripta
A partnership between two CRISPR pioneers will provide the global scientific community with GMP and RUO MAD7 Nuclease
May 3, 2022
Inside Inscripta: Jamie Schwendinger-Schreck, Applications Development
As we continue to add to the Onyx® platform’s capabilities, we have countless research projects underway here at Inscripta. It takes a very…
April 18, 2022
Highlights from the 2022 Built With Biology conference
After two-and-a-half years, the synthetic biology industry gathered again in person at the Built With Biology Global Synthetic Biology…
April 4, 2022
Updating the human reference genome and the impact on the future of genome editing
In 2001, after 11 years of work and nearly half-a-billion dollars in US government funding, two initial versions of a human reference assembly…
March 29, 2022
4 Myths of Forward Engineering
We’ve talked about the different approaches to engineering biology in the previous blog post. Now let’s take a look at some common…
March 15, 2022
“Get Ready to be Surprised” – Patrick Westfall’s interview for Built With Biology podcast
Patrick Westfall and Fiona Mischel talk about the approaches and mindset for engineering biology in a recent Built With Biology podcast “How Do…
March 1, 2022
Inside Inscripta: Alia Clark-ElSayed, Applications Development
As our company grows, we get to bring fresh talent on our team. Today our spotlight is on Alia Clark-ElSayed, Research Associate on the…
February 22, 2022
Highlights from the 2021 Genome Engineering Biosecurity Workshop
Biosecurity remains one of our top priorities, and we recently organized a discussion-based virtual workshop titled “Genome Engineering and…
February 15, 2022
Introducing the Onyx® Iterative Genome Engineering workflow for rapid strain improvement
Inscripta recently launched a new feature to expand what you can do with the Onyx platform – Iterative Genome Engineering, which enables…